[Form 4] CryoPort, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Robert J. Hariri, a director of Cryoport, Inc. (CYRX), reported a sale of 5,000 shares of the company's common stock on 08/22/2025 at a reported price of $8.60 per share. Following this transaction he beneficially owned 26,275 shares, held directly. The Form 4 discloses only this non-derivative sale and contains no additional explanation.

Insights

Corporate Governance Expert

TL;DR: Director sold a modest portion of holdings; routine disclosure shows reduced direct ownership after a single open-market sale.

The reported sale of 5,000 shares at $8.60 reduces the director's direct stake to 26,275 shares. This filing is a standard Section 16 disclosure intended to inform investors of insider trading activity. No derivative transactions, option exercises, or 10b5-1 plan indicators are reported, and no explanatory remarks are provided.

Securities Analyst

TL;DR: Single-share sale reported; impact on capitalization is minimal based on disclosed quantities.

The transaction appears to be a simple disposition of common stock rather than a strategic corporate action. The sale amount and remaining ownership are explicitly stated. There is no information in the filing about motivations, larger pattern of trades, or changes to overall ownership structure, limiting inference about material market impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hariri Robert J

(Last) (First) (Middle)

C/O CRYOPORT INC.112

WESTWOOD PLACE, SUITE 350

(Street)

BRENTWOOD TN 37027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cryoport, Inc. [ CYRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		S		5,000	D	$8.6	26,275	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Robert J. Hariri	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cryoport (CYRX) report for Robert J. Hariri?

The Form 4 reports a sale of 5,000 shares of Cryoport common stock by director Robert J. Hariri on 08/22/2025 at $8.60 per share.

How many Cryoport shares does Robert J. Hariri own after the reported sale?

Following the reported transaction, he beneficially owned 26,275 shares, held directly.

Does the Form 4 show any option exercises or derivative transactions for Hariri?

No. Table II (derivative securities) contains no reported transactions; only a non-derivative sale is disclosed.

Is there any explanation provided for the sale in the Form 4?

No explanatory remarks are included in the filing; the form lists only the transaction details and signature.